Compounds > fingolimod hydrochloride

Page last updated: 2024-09-02

fingolimod hydrochloride and Immune Reconstitution Disease

fingolimod hydrochloride has been researched along with Immune Reconstitution Disease in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	5 (62.50)	24.3611
2020's	3 (37.50)	2.80

Authors

Authors	Studies
Afanasjeva, B; Afanasjevas, D; Baltusiene, A; Berger, JR; Gleizniene, R; Mickeviciene, D; Rastenyte, D	1
Adams, O; Aktas, O; Albrecht, P; Gembruch, O; Gold, R; Hadisurya, J; Hartung, HP; Hellwig, K; Kraemer, M; Pilgram-Pastor, S; Schneider-Hohendorf, T; Schwab, N; Sinnecker, T; Wrede, K	1
Derfuss, T; Fischer-Barnicol, B; Kappos, L; Kuhle, J; Lorscheider, J; Oechtering, J	1
Alkabie, S; Cuascut, FX; Hutton, GJ	1
Ayzenberg, I; Deguchi, K; Gold, R; Kamada, M; Kufukihara, K; Kume, K; Nakahara, J; Schneider, R; Takata, T; Tomaske, L	1
Almulla, A; Alroughani, R; Lamdhade, S; Thussu, A	1
Brew, BJ; Calic, Z; Cappelen-Smith, C; Cuganesan, R; Hodgkinson, SJ; McDougall, A	1
Bertolotto, A; Caldano, M; Lugaresi, A; Marnetto, F; Spadaro, M	1

Other Studies

8 other study(ies) available for fingolimod hydrochloride and Immune Reconstitution Disease

Article	Year
Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation? A case report. BMC neurology, 2022, Aug-19, Volume: 22, Issue:1 Topics: Brain; Fingolimod Hydrochloride; Humans; Immune Reconstitution Inflammatory Syndrome; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Natalizumab	2022
Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. BMC neurology, 2019, Aug-09, Volume: 19, Issue:1 Topics: Adult; Fingolimod Hydrochloride; Humans; Immune Reconstitution Inflammatory Syndrome; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting	2019
Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML. Neurology(R) neuroimmunology & neuroinflammation, 2021, Volume: 8, Issue:1 Topics: Adjuvants, Immunologic; Antiviral Agents; Crotonates; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immune Reconstitution Inflammatory Syndrome; Immunosuppressive Agents; Interferon beta-1a; Leukoencephalopathy, Progressive Multifocal; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Toluidines	2021
Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis. Multiple sclerosis and related disorders, 2021, Volume: 53 Topics: Fingolimod Hydrochloride; Humans; Immune Reconstitution Inflammatory Syndrome; Immunosuppressive Agents; Meningitis, Cryptococcal; Meningoencephalitis; Multiple Sclerosis	2021
Three cases of non-carryover fingolimod-PML: Is the risk in Japan increased? Neurology(R) neuroimmunology & neuroinflammation, 2019, Volume: 6, Issue:3 Topics: Europe; Female; Fingolimod Hydrochloride; Humans; Immune Reconstitution Inflammatory Syndrome; Immunosuppressive Agents; Japan; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Multiple Sclerosis	2019
Multiple sclerosis reactivation postfingolimod cessation: is it IRIS? BMJ case reports, 2014, Oct-15, Volume: 2014 Topics: Adult; Antibodies, Monoclonal, Humanized; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immune Reconstitution Inflammatory Syndrome; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Propylene Glycols; Recurrence; Sphingosine	2014
Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2015, Volume: 22, Issue:3 Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immune Reconstitution Inflammatory Syndrome; Immunoglobulins, Intravenous; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Natalizumab; Retreatment; Treatment Outcome	2015
Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells. Journal of neuroinflammation, 2015, Aug-12, Volume: 12 Topics: Adult; Aged; CD4-Positive T-Lymphocytes; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immune Reconstitution Inflammatory Syndrome; Immunologic Factors; Interferon-beta; L-Selectin; Leukocyte Count; Male; Middle Aged; Monocytes; Multiple Sclerosis; Natalizumab; Rituximab; Young Adult	2015